Tagged with Biologics

Japan Osamu Nagayama, president of the Japan BioIndustry Association (JBA) and chairman and CEO of Chugai Pharmaceutical, discusses Japan’s footprint in biologics and how mergers between Japanese pharma companies, thereby creating larger R&D funding pools, could hold the key to future success in the biotechnology field. Can you begin by introducing…

Canada Stefan Larson, CEO of Northern Biologics, explains the major milestones for Northern Biologics over the past three years, his personal motivation for starting a biotech company, their collaboration with Celgene, and his thoughts on the strengths and areas for growth within the Canadian biotech industry. Stefan, three years into the…

Austria Maria Seriakov, CEO and founder of M bioserviceS, a young Austrian company dealing globally that specialises in logistics, regulatory affairs and quality control of biologics, discusses the challenges of navigating differing regulations across the globe as well as the how a hands-on approach ensures a product’s high quality. Furthermore, she…

Indonesia Ashish D. Pal, President Director at MSD Indonesia, discusses the importance of introducing innovative pharmaceuticals, vaccines and biologics to address significant unmet needs and the strategic importance of the universal healthcare coverage program (JKN) towards meeting the national healthcare goals. Mr. Pal, you have been leading the Indonesian affiliate of…

Taiwan Eric Tsao, founder of Synermore Biologics, talks about how a company employing 90 people can successfully operate internationally and efficiently progress with its biosimilar and innovative product development pipeline. He also discusses what business strategy and potential partnerships will determine the successful growth of the company in the future. You…

Switzerland www.celonic.com CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and what makes it the partner of choice in Switzerland and beyond. Celonic is in many ways more than a CDMO for biologics. What is the strategic focus of this company? “Our…

Taiwan The co-founder and president of Mycenax Biotech, Dr. Karen Wen details the key lessons learned from the development of their first in-house product TuNEX® and how they have been applied to their second flagship product LusiNEX (tocilizumab). She also details the company’s transition from a platform-driven service provider to a…

Singapore Having recently obtained cGMP from Singapore’s Health Sciences Authority, the founders of PrIME Biologics showcase the role of PrIME Technology in driving plasma self-sufficiency in Asia, while highlighting how this innovative technology is disrupting industry standards of plasma fractionation. Could you please introduce to our international readers the background underlying…

Pharma MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth. The headline-making news at the moment is…

Research NIBRT’s projects director discusses the new ‘Biologic’ center for biologics research, business development, training, and commercializing the organisation’s extensive research capabilities. As Projects Director, you are responsible for driving NIBRT’s growth and development, in terms of both research and bioprocessing training. What’s the most exciting opportunity that NIBRT is currently working on?…

Pharma FDI into Irish pharma has almost exclusively targeted in biologics production over the last few years, largely due to Ireland’s skilled workforce of bioprocessing technicians. NIBRT director Dominic Carolan discusses how the institute supports the Irish biopharma industry through training and recruitment solutions, while pursuing research that may help to…

Pharma Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are now accelerating their investment in biologics. As the national champion in the healthcare sector, what is the importance of Sanofi…